Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria

Diabetes Care

Volumn 32, Issue 10, 2009, Pages 1873-1879

  Persson, Frederik ^a   Rossing, Peter ^a   Reinhard, Henrik ^a   Juhl, Tina ^a   Stehouwer, Coen D A ^b   Schalkwijk, Casper ^b   Jan Danser, A H ^c   Boomsma, Frans ^c   Frandsen, Erik ^d   Parving, Hans Henrik ^e,f  

^a STENO DIABETES CENTER   (Denmark)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^e Mental Health Services CPH   (Denmark)

^f AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; FUROSEMIDE; IRBESARTAN; PLACEBO;

ALBUMINURIA; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOMAGNESEMIA; HYPOTENSION; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PNEUMONIA; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; URINARY TRACT INFECTION;

AGED; ALBUMINURIA; AMIDES; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; TETRAZOLES; TREATMENT OUTCOME;

EID: 70349690296     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-0168     Document Type: Article

References (25)

1. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860 (Pubitemid 34940824)
2. Rossing P, Hommel E, Smidt UM, Parving H-H. Reduction in albuminuria predicts a beneficial effect on progression in diabetic nephropathy during antihypertensive treatment. Diabetologia 1994;37:511-516 (Pubitemid 24133655)
3. Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878 (Pubitemid 34940826)
4. Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CDA, Schalkwijk C, Boomsma F, Frandsen E, Parving H-H. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008;73:1419-1425 (Pubitemid 351770494)
5. Parving H-H, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-2446 (Pubitemid 351793017)
6. Bröchner-Mortensen J. A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 1972;30:271-274
7. Hostetter TH, Troy JL, Brenner BM. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 1981;19:410-415 (Pubitemid 11112621)
8. Trevisan R, Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am J Hypertens 1995;8:876-883
9. Imanishi M, Yoshioka K, Konishi Y, Okumura M, Okada N, Sato T, Tanaka S, Fujii S, Kimura G. Glomerular hypertension as one cause of albuminuria in type II diabetic patients. Diabetologia 1999;42:999-1005 (Pubitemid 29369609)
10. Andersen S, Blouch K, Bialek J, Deckert M, Parving H-H, Myers BD. Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney Int 2000;58:2129-2137 (Pubitemid 30807942)
11. Langham RG, Kelly DJ, Cox AJ, Thomson NM, Holthofer H, Zaoui P, Pinel N, Cordonnier DJ, Gilbert RE. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002;45:1572-1576 (Pubitemid 35352051)
12. Fisher NDL, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008;117:3199-3205
13. Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002;347:1256-1261 (Pubitemid 35176246)
14. Azizi M, Bissery A, Lamarre-Cliche M, Menard J. Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans. Hypertension 2004;43:785-790 (Pubitemid 38405588)
15. Azizi M, Menard J, Bissery A, Guyenne TT, Bura-Riviere A, Vaidyanathan S, Camisasca RP. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004;15:3126-3133 (Pubitemid 39578845)
16. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370:221-229 (Pubitemid 47069535)
17. Rossing K. Progression and remission of nephropathy in type 2 diabetes: new strategies of treatment and monitoring. Dan Med Bull 2007;54:79-98 (Pubitemid 46845727)
18. Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 2007;20:587-597
19. Danser AHJ, Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension 2005;46:1069-1076
20. Batenburg WW, de Bruin RJA, van Gool JMG, Muller DN, Bader M, Nguyen G, Danser AHJ. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008;28:1151-1157
21. Frandsen E, Boomsma F, Persson F, Dieterich HA, Yeh CM, Dole WP, Lund ED, Prescott M. Renin measurements in the presence of the oral direct renin inhibitor aliskiren: development and validation of a novel high-sensitivity plasma renin activity (hsPRA) assay for measurement of bioactive renin. J Hypertens 2008;26:S383
22. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991;324:1098-1104
23. Parving H-H, Brenner BM, McMurray J, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009;24:1663-1671
24. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-553
25. Bakris GL, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, de Champlain J, Weber MA, Raz I. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial. Kidney Int 2007;72:879-885 (Pubitemid 47462081)